From Darkness to Discovery: My Year Testing San Francisco’s Most Experimental Depression Treatments
Ketamine and TMS walked into my life during one of the lowest periods I can remember. After nearly a decade of cycling through traditional antidepressants, therapy modalities, and wellness rituals that ranged from genuinely helpful to borderline absurd, I found myself sitting in a sleek San Francisco clinic, signing consent forms for treatments that, just a few years earlier, would have seemed ripped from a science fiction novel. What followed was twelve months of neurological experimentation, surprising breakthroughs, uncomfortable setbacks, and a completely transformed understanding of what treating depression actually means in the modern era.
This is not a medical endorsement. This is my story — honest, messy, and as complete as memory allows.
—
How I Ended Up in San Francisco’s Experimental Mental Health Scene
San Francisco has become something of a quiet capital for cutting-edge psychiatric care. Between the city’s culture of innovation, its concentration of research institutions, and a patient population that tends to be both open-minded and medically informed, the Bay Area has cultivated a remarkable ecosystem of clinicians willing to push beyond the SSRIs-and-therapy playbook.
I arrived at this ecosystem exhausted. My psychiatrist of six years had described my depression as “treatment-resistant” — a clinical term that sounds almost bureaucratic until you realize it means your brain has systematically rejected every conventional tool medicine has tried to offer it. When she mentioned ketamine infusions and Transcranial Magnetic Stimulation (TMS) in the same conversation, I went home and spent three weeks researching both before saying yes.
—
Understanding Ketamine Therapy: What Actually Happens
The Ketamine Experience in Clinical Settings
Ketamine, originally developed as an anesthetic and still widely used in emergency medicine, has emerged as one of the most exciting rapid-acting interventions in psychiatric history. Unlike SSRIs, which can take four to six weeks to produce any measurable effect, ketamine works on the glutamate system — specifically targeting NMDA receptors — and can produce antidepressant effects within hours.
My infusion protocol consisted of six sessions over three weeks at a clinic in the Mission District. Each session lasted approximately forty minutes. I was reclined in a comfortable chair, given a low-dose IV infusion, and encouraged to wear an eye mask and listen to a curated playlist. The experience itself is genuinely difficult to describe to anyone who hasn’t had it. Perceptual distortions, a profound sense of detachment from my body, moments of inexplicable beauty, and occasionally, waves of existential discomfort I hadn’t anticipated.
What nobody tells you clearly enough is that the dissociative experience — the so-called “journey” — is not the treatment. The neuroplasticity that occurs in the hours and days following infusion is where the therapeutic work happens. My clinic paired infusions with integration therapy sessions, which I found absolutely essential. Without that psychological scaffolding, I suspect the ketamine effects would have faded within weeks rather than lasting months.
What the Research Actually Says
Studies published in journals including JAMA Psychiatry and the New England Journal of Medicine have documented response rates for ketamine in treatment-resistant depression between 50 and 70 percent — numbers that are striking compared to conventional treatments. The FDA-approved nasal spray esketamine (Spravato) has made the compound more accessible, though many clinicians still prefer IV infusions for their precision and immediate effect.
The catches are real, though. Ketamine is expensive — my protocol ran approximately $4,500 out of pocket, with no insurance coverage. Effects are not permanent for most patients, requiring maintenance sessions every few months. And the long-term safety profile, particularly around potential dependency and cognitive effects with frequent use, is still being studied.
—
TMS Therapy: The Quieter Revolution
What Transcranial Magnetic Stimulation Actually Does
If ketamine is the dramatic, cinematic protagonist of this story, TMS is the quiet, methodical character who turns out to matter just as much. Transcranial Magnetic Stimulation uses precisely targeted magnetic pulses to stimulate specific regions of the brain — primarily the dorsolateral prefrontal cortex, an area consistently underactive in people with depression.
I began a TMS protocol six months into my year of experimentation, overlapping with my ketamine maintenance sessions. Standard TMS typically involves five sessions per week for six weeks. Each session lasts about twenty minutes. You sit upright in a specialized chair while a device positioned against your head delivers rhythmic pulses that feel like a woodpecker gently tapping your skull. It is entirely non-invasive. There is no sedation, no altered state, no downtime. You can drive yourself home and return to work immediately.
The TMS Protocol That Changed My Mornings
The version I received was accelerated TMS — sometimes called Stanford Neuromodulation Therapy or SNT — a compressed protocol that delivers the full course in days rather than weeks through multiple sessions per day. The research behind this approach, pioneered at Stanford, has shown response rates exceeding 80 percent in some studies, with results appearing far faster than traditional TMS.
By week two, I noticed something subtle but unmistakable: I was waking up without the lead-blanket heaviness that had been my morning companion for years. The cognitive fog that made early hours feel like moving through wet cement began to lift. My therapist noted I was making connections in sessions that had previously felt blocked.
TMS is not without its limitations. It requires significant time commitment, insurance coverage is inconsistent though improving, and approximately one-third of patients do not respond meaningfully. Headaches following sessions are common. And the neurological benefits, like ketamine, require periodic maintenance for many patients.
—
Combining Both Treatments: What Nobody Warned Me About
One of the most significant and underreported aspects of pursuing both treatments simultaneously is the complexity of tracking what is working. When your brain is being targeted by two profoundly different neurological interventions at the same time, attribution becomes genuinely difficult. Was the emotional flexibility I experienced in month eight from ketamine’s neuroplastic effects? From TMS rewiring prefrontal connectivity? From the integration therapy? From simple time and lifestyle changes that run parallel to any intensive mental health protocol?
My psychiatrist and I kept detailed symptom journals throughout the year. What emerged was a picture of complementary mechanisms: ketamine seemed to produce powerful but time-limited windows of emotional openness and reduced suicidal ideation; TMS appeared to create more durable, structural changes in mood baseline. Together, they produced something neither seemed to achieve as reliably alone.
—
The Honest Reckoning
Twelve months later, I am meaningfully better. Not cured — depression does not work like a broken bone that heals cleanly. But the floor of my worst days is higher than it has ever been. I have a maintenance ketamine session every eight weeks. I completed a second TMS protocol earlier this year. I still see a therapist weekly.
What San Francisco’s experimental treatment landscape gave me was not a magic answer but something arguably more valuable: options. For the estimated 30 percent of depression patients who do not respond to first-line treatments, these interventions represent not fringe medicine but genuine frontiers of care — rigorous, research-backed, and increasingly accessible.
If you are in that 30 percent and feel like you have run out of roads, you probably haven’t. The map just needs updating.
—
Always consult qualified mental health professionals before pursuing any psychiatric treatment. This article reflects one individual’s personal experience and is not intended as medical advice.
